FibroGen Receives Milestone from US/China Partner AstraZeneca
publication date: May 7, 2015
FibroGen of San Francisco received a $15 million milestone from AstraZeneca for roxadustat, a novel clinical-stage treatment for anemia. AstraZeneca in-licensed US and China rights for roxadustat in 2013, paying $350 million upfront and up to $450 million in milestones. In China, FibroGen is in charge of obtaining CFDA approval of roxadustat, but AstraZeneca will be responsible for marketing the drug there. FibroGen expects to submit an NDA for approval of roxadustat in China in 2016, before a planned 2018 filing in the US. More details....
Stock Symbols: (NSDQ: FGEN) (NYSE: AZN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.